Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

CAR-T

Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial

The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma. ALLO-647 was being used as a preparative lymphodepletion therapy.

August 4, 2025

1 min read

Tristan Manalac

Doubtful person, hands on hips, choosing the way as multiple arrows on the road showing a mess of different directions. Choosing the correct pathway, difficult decision concept, confusion symbol.

Obesity

CMS Mulls About-Face in Coverage of GLP-1 Treatments for Obesity: Report

Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration, to include anti-obesity medications in Medicare Part D coverage.

August 4, 2025

2 min read

Tristan Manalac

[Figure 1.] Syracuse Bio Campus – Home to LOTTE BIOLOGICS’ ADC and monoclonal antibody (mAb) manufacturing facilities

Sponsored

LOTTE BIOLOGICS Accelerates Global CDMO Expansion with Dual Manufacturing Bases in North America and Asia, and Next-Generation ADC Modalities

This year, LOTTE BIOLOGICS has ramped up its CDMO business expansion with the completion of an ADC (Antibody-Drug Conjugate) facility expansion at its Syracuse Bio Campus in the U.S. and the signing of its first production contract.

August 4, 2025

3 min read

Human brain with abstract visualization of neuron activity

Brain Cancer

Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table

After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding and renewed interest from companies like Merck and Jazz Pharmaceuticals.

August 4, 2025

6 min read

Ben Hargreaves

businesspeople talking through messy chaos, tangled phone line make other confused miscommunicate unclear message and informationBad communication concept vector

FDA

‘Unprecedented’ FDA Leaks Sow Confusion for Patients, Sarepta and Capricor

Sarepta and Capricor learned of key regulatory decisions from the media and investors, and Duchenne muscular dystrophy families have turned to the news for answers. Meanwhile, the FDA insists it remains committed to notifying companies of any regulatory action before sharing information with the media or public.

August 4, 2025

7 min read

Heather McKenzie

Creative photo poster picture collage collapsing dollar banknote arm holding cash money bankrupt decrease income funds loss.

Opinion

How Biotechs Can Navigate NIH Cuts

A ripple effect of the NIH’s slashed 2026 budget will be felt throughout the biopharma ecosystem. Young companies must act now to weather the storm.

August 4, 2025

5 min read

Justin Kozak

Earnings

Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.

August 1, 2025

2 min read

Tristan Manalac